US2023277580A1PendingUtilityA1

Cell protective methods and compositions

65
Assignee: UNIV NORTH CAROLINA CHAPEL HILLPriority: Jun 20, 2018Filed: Apr 24, 2023Published: Sep 7, 2023
Est. expiryJun 20, 2038(~11.9 yrs left)· nominal 20-yr term from priority
Inventors:Jian LiuJine LiGuowei SuRafal PawlinskiErica Sparkenbaugh
A61K 31/737A61P 39/02A61P 31/04
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.

Claims

exact text as granted — not AI-modified
1 - 8 . (canceled) 
     
     
         9 . A pharmaceutical composition for use in treating histone toxicity and/or sepsis, the composition comprising one or more chondroitin sulfate compounds and a pharmaceutically acceptable carrier. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof. 
     
     
         11 . The pharmaceutical composition of  claim 9 , wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof. 
     
     
         12 . The pharmaceutical composition of  claim 9 , wherein the chondroitin sulfate compound comprises one or more of the following structures: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of —H, alkyl (such as but not limited to —CH 3  or —CH 2 CH 3 ), substituted alkyl, aryl, and substituted aryl (such as but not limited to a p-nitrophenyl group), wherein n is 1, 2, 3, 4, 5, 6, 7 or 8. 
       
     
     
         13 - 19 . (canceled)

Join the waitlist — get patent alerts

Track US2023277580A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.